{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-012154","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2023-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.798534+00:00","generated_at":"2026-06-17T02:39:36.935449+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oncocyte cuts ~20% of workforce; expects $0.3M severance charges in Q2 2023","bullets":["Reduction in force involving approximately 20% of employees, announced April 12, 2023.","Estimated charges of about $0.3 million for severance and benefits in Q2 2023.","Management says cuts align with kitted product strategy and extend cash runway into 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-012154","json":"https://secwatch.observer/filing/0001493152-23-012154.json","markdown":"https://secwatch.observer/filing/0001493152-23-012154.md","text":"https://secwatch.observer/filing/0001493152-23-012154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223012154/0001493152-23-012154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223012154/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:39:36.935449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76bd071d1818412fd4dff9b549dcec6f48893471","claim":"Insight Molecular Diagnostics Inc. announced a restructuring with charges of approximately $0.3 million related to employee severance and benefits costs affecting workforce (approximately 20% of its workforce).","evidence_excerpt":"On April 12, 2023, Oncocyte Corporation (the “Company” or “Oncocyte”) , announced a reduction in force involving approximately 20% of its workforce (the “Reduction”), which management believes will extend Oncocyte’s cash runway in 2024. In connection with the Reduction, Oncocyte estimates that it will incur charges of approximately $0.3 million related to employee severance and benefits costs in the second quarter of 2023.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223012154/0001493152-23-012154-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.3 million related to employee severance and benefits costs"},{"label":"Affected area","value":"workforce"},{"label":"Headcount","value":"approximately 20% of its workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}